Summary: DNA double-strand breaks (DSBs) represent dangerous chromosomal lesions that can lead to mutation, neoplastic transformation, or cell death. DSBs can occur by extrinsic insult from environmental sources or may occur intrinsically as a result of cellular metabolism or a genetic program. Mammalian cells possess potent and efficient mechanisms to repair DSBs, and thus complete normal development as well as mitigate oncogenic potential and prevent cell death. When DSB repair (DSBR) fails, chromosomal instability results and can be associated with tumor formation or progression. Studies of mice deficient in various components of the non-homologous end joining pathway of DSBR have revealed key roles in both the developmental program of B and T lymphocytes as well as in the maintenance of general genome stability. Here, we review the current thinking about DSBs and DSBR in chromosomal instability and tumorigenesis, and we highlight the implications for understanding the karyotypic features associated with human tumors.
Introduction
The mammalian genome is at constant risk of mutation as a result of damage to chromosomal DNA. DNA damage can occur by intrinsic insults, such as base pair mismatches during DNA replication, collapse of replication forks, and attack by reactive oxygen species produced during normal cellular metabolism, or as part of a developmental program. DNA damage can also occur by extrinsic insult such as exposure to ultraviolet light, ionizing radiation, or environmental mutagens. One particularly harmful form of DNA damage is the double-strand break (DSB). Unrepaired DSBs have severe consequences that include cell death or neoplastic transformation. To ensure the high fidelity replication and to promote the faithful transmission of accurate and intact genetic information, cells require sophisticated mechanisms to sense and repair DSBs (reviewed in 1).
One well-established consequence of improperly repaired DSBs is the induction of chromosomal abnormalities. Analysis of cells with deficiencies in DSB repair (DSBR) revealed a high predisposition to translocations, especially following exposure to DSB-inducing agents (reviewed in 2). Formation of translocations is dangerous. Deletions, genetic misregulation, or aneuploidy can result, and translocations can generate fusion genes encoding proteins with novel properties. DSBs have also been implicated in the initiation of gene amplification, which can result in imbalances in factors critical for maintaining cellular homeostasis. Moreover, activation of oncogenes by translocation or amplification is a predominant mechanism for cellular transformation and tumorigenesis. It is therefore important to understand the molecular mechanisms that prevent such events from occurring in normal cells and to elucidate molecular mechanisms that promote such aberrations when protective faculties fail.
Mammalian cells depend on at least two general processes to effect repair of DSBs: homologous recombination (HR), which promotes accurate repair of DSBs by copying intact information from an undamaged homologous DNA template and non-homologous end joining (NHEJ), which is a homologyindependent mechanism that rejoins broken ends irrespective of sequence (reviewed in 1). Inability to carry out either of these modes of DSBR can result in substantial genomic instability, hypersensitivity to DNA damage, and in some cases, immune deficiencies or tumor susceptibility. Although both pathways function in many, if not all, vertebrate cell types, studies of lymphocyte development have proven to be uniquely informative concerning the roles of NHEJ in maintaining genome stability and preventing tumorigenesis. This review will focus on the role of NHEJ in repairing DSBs, preventing genome instability, and suppressing tumorigenesis.
V(D)J recombination: DNA double-strand breaks and repair by non-homologous end joining DNA breaks
Programmed DSBs occur during the development of B and T lymphocytes. Developing lymphocytes assemble functional antigen receptor genes by the ordered rearrangement of component variable (V), diversity (D), and joining (J) gene segments, in a reaction known as V(D)J recombination (reviewed in 3, 4) . V(D)J recombination occurs within immunoglobulin (Ig) or T-cell receptor (TCR) loci and is targeted by recombination signal (RS) sequences that flank each component gene segment. RS sequences are composed of relatively conserved palindromic heptamer and AT-rich nonamer sequences separated by a 12-bp or 23-bp spacer sequence. Recombination occurs only when one recombining RS sequence contains a 12-bp spacer and the partner RS sequence contains a 23-bp spacer. V(D)J recombination is initiated by the introduction of a DNA DSB between a V, D, or J coding segment and its associated RS sequence (see below). The cleavage reaction results in the liberation of two, blunt, 5 0 phosphorylated RS ends, which can be directly ligated, and two covalently sealed hairpin coding ends, which must be opened before joining can occur. If recombining RS sequences are divergently oriented, the RS-joining reaction produces an excised circular DNA containing the RS joint along with chromosomal DNA contained between the two RS sequences. By contrast, tandemly oriented RS sequences result in a chromosomal inversion, following coding and RS joining.
The RAG endonuclease
The V(D)J recombination reaction is initiated by the introduction of site-specific DSBs by the RAG1/2 endonuclease complex, which recognizes and binds to recombining RS sequences and catalyzes a transesterification reaction that generates both the blunt RS ends and the hairpin-coding ends (reviewed in 5). The RAG1/2 complex is absolutely required for V(D)J recombination to occur and mice deficient in either the RAG1 or RAG2 gene exhibit a complete block at the progenitor stage of both B-and T-cell development. However, RAG activity is restricted to the lymphoid lineage, and RAGdeficient mice do not display any other overt phenotypes (reviewed in 3). V(D)J recombination in both B-and T-cell lineages occurs in a precisely ordered fashion (6) . In developing B-lineage cells, IgH genes are assembled first, via an ordered process in which D to J H rearrangements are followed by V H to DJ H joining. In developing lymphocytes, RAG expression first occurs in early lineage-committed progenitor cells (reviewed in 9, 10). In pro-B cells, RAG expression is initially low, and it increases as cells mature (reviewed in 9, 10). RAG expression decreases during the expansion of heavy chain-expressing cells and becomes reactivated to induce recombination in Ig light chain genes (reviewed in 9-11). While ongoing RAG expression in newly generated B cells allows 'receptor editing', RAG expression is not observed in most mature peripheral B cells (12, 13) 
Repair by non-homologous end joining
Assessment of V(D)J-recombination efficiency in ionizing radiation (IR)-sensitive Chinese hamster ovary (CHO) cells and murine severe combined immunodeficiency disease (SCID) cell lines revealed that RAG-dependent DSBs induced during V(D)J recombination are joined by the NHEJ pathway (15) (16) (17) . The known factors that make up the NHEJ pathway are the following: the DNA-dependent protein kinase (DNA-PK), consisting of the DNA-PK catalytic subunit (DNA-PKcs) and the end-binding heterodimer Ku70/Ku80; the recently characterized factor Artemis; and DNA ligase IV (Lig4) plus its associated factor XRCC4 (reviewed in 3). Ku70 and Ku80 as well as XRCC4 and Lig4 are required for both coding and RS-joint formation during V(D)J recombination (reviewed in 3). Cells that are deficient in any of these four factors are severely compromised for both joining reactions (reviewed in 3). The Ku complex could have a number of roles in NHEJ, including keeping broken ends in proximity, protection of broken ends from promiscuous enzymatic attack, or recruitment of other factors such as DNA-PKcs or the XRCC4/Lig4 complex (reviewed in [18] [19] [20] . The latter complex appears to be specifically required for the ligation step of NHEJ. Ku70, Ku80, XRCC4, and Lig4 are evolutionarily conserved and have homologs in yeast (reviewed in 21, 22) , while DNA-PKcs and Artemis appear to have evolved in vertebrates (reviewed in 21).
DNA-PKcs is a member of the phosphoinositide 3 kinase (PI3K) family of protein kinases which also includes the ataxia telangiectasia-mutated (ATM) protein (23) . DNA-PKcs kinase activity is activated by the interaction of the catalytic subunit with the DNA-bound Ku complex. In V(D)J recombination, DNA-PKcs is required for coding end joining but not for RS joining, indicating that DNA-PKcs is not strictly required for all NHEJ reactions (reviewed in 24). The requirement of Ku, but not DNA-PKcs, for RS joining also reveals a DNA-PKcsindependent role for Ku in NHEJ (reviewed in 3), which may be recruitment of XRCC4/Lig4 (25) . The findings that DNAPKcs-deficient cells are compromised for coding joint formation and produce unusually large P elements suggested that DNA-PK might participate in coding end processing (reviewed in 26). Various DNA-PKcs substrates have been implicated based on in vitro studies, but recent evidence has pointed strongly to Artemis. Artemis was identified based on its common mutation in a pair of related human SCID syndromes, SCIDA and radiation sensitive (RS)-SCID (27, 28) , which are characterized by severe immune deficiency and hypersensitivity to ionizing radiation (27) (28) (29) (30) . Like DNA-PKcs, Artemis deficiency preferentially affects coding, as opposed to RS-joint formation, suggesting that it is also involved in hairpin processing (27, 28, 30, 31) . This notion received strong support when it was shown that a complex of Artemis and DNA-PKcs is capable of opening covalently sealed hairpin coding ends in vitro (32) and is necessary for normal opening of RAG-generated hairpin ends in vivo (31) . These and other findings have led to the suggestion that Artemis and DNA-PKcs may have evolved to process a subset of DNA ends (e.g. hairpins) that cannot be directly joined by the conserved NHEJ components (31, 32, 33) .
Non-homologous end joining and general genome stability
Mice deficient in each of the known NHEJ factors have been generated. The severity of the overall phenotype for each knockout mouse generally mirrors the severity of the V(D)J defect seen in the corresponding NHEJ-deficient cells (reviewed in 3). Mice deficient in either DNA-PKcs or Artemis exhibit a severe combined immune deficiency due to the defect in coding joint formation in both B and T cells, but they display no other overt phenotypes (31, (33) (34) (35) (36) . Embryonic fibroblasts derived from these mice show elevated sensitivity to IR as well as spontaneous chromosomal anomalies including breaks, translocations, and telomere fusions (31, 35, 37) . However, mouse embryonic stem (ES) cells mutant in either DNA-PKcs or Artemis do not display IR sensitivity, suggesting cell-type differences in the requirement of general NHEJ factors (35, 33) . Ku70-and Ku80-deficient mice, in addition to being compromised for lymphocyte development, are also proportional dwarfs, and their cells show hypersensitivity to IR and prematurely senesce (reviewed in 3).
Ku-deficient mice also display increased genomic instability in all cells types examined (reviewed in 3). The greater severity of the knockout phenotype in mice also supports the notion that Ku70 and Ku80 have functions beyond those of the DNA-PK holoenzyme.
Cultured cells deficient in DNA Lig4 or XRCC4 have phenotypes similar to Ku deficiency. Like other NHEJ factors in mice, Lig4 and XRCC4 are required for the maintenance of genome stability as shown by a high level of spontaneous chromosomal abnormalities, including simple and complex translocations (reviewed in 2). However, homozygous inactivation of either XRCC4 or Lig4 in mice results in embryonic lethality (39) (40) (41) . Histologic analyses of the developing nervous systems of Lig4-, XRCC4-, and Ku70-deficient embryos revealed substantial apoptosis in postmitotic neurons, in a pattern that correlates with the normal gradient of neuronal differentiation (39, 40, 42) . This phenotype is more severe in Lig4-and XRCC4-deficient embryos than in Ku-deficient embryos, and it is not seen in DNA-PK or Artemis-deficient embryos (31, 42) . Although other possibilities remain, these findings led to the speculation that the more severe relative impairment of NHEJ may result in the embryonic lethality in Lig4-or XRCC4-deficient mice but not Ku70-or Ku80-deficient mice (43) . In this regard, it is quite notable that Ku deficiency rescues embryonic lethality in Lig4-deficient mice, perhaps by allowing broken ends to be repaired by another pathway (44) .
The embryonic lethality and neuronal apoptosis conferred by Lig4 or XRCC4 deficiency are rescued by deficiency of the p53 tumor suppressor protein (45, 46) . This finding indicates that these defects result primarily from a p53 response to unrepaired DSBs rather than from inability to repair the DSBs via NHEJ per se. Why cells of this lineage are so susceptible to unrepaired DSBs remains an intriguing question. Deficiency of p53 also rescues cellular proliferation and prevents premature senescence in Lig4-or XRCC4-deficient fibroblasts. Notably, p53 deficiency rescues the size of the pro-B-cell population in XRCC4-or Lig 4-deficient mice, consistent with the notion that these cells die from a p53 response to unrepaired RAGinitiated DSBs. However, p53 deficiency does not restore V(D)J recombination or further differentiation of NHEJdeficient pro-B cells, as NHEJ is required to repair the RAGinitiated DSBs and assemble the functional antigen receptor genes required for lymphocyte development (45, 46) . While newborn XRCC4/p53 (X/P) or Lig4/p53 (L/P) doubledeficient mice are viable, they are significantly smaller than normal littermates, similar to Ku80/p53-deficient mice (K/P) (47) and routinely succumb to progenitor B-cell malignancies by 6-12 weeks after birth (discussed further below).
Other sources of DNA breaks
Class switch recombination and somatic hypermutation In peripheral lymphoid organs, such as spleen and lymph nodes, naïve B cells, usually in association with T cells, undergo antigen-driven clonal expansion in germinal centers (GCs). At this time, B cells also may undergo class switch recombination (CSR) and somatic mutation (SM). Differentiating B lymphocytes first produce m heavy chains, but upon activation, they can join the V(D)J exon to downstream C H exons by CSR, allowing the generation of a different antibody class with different effector function (reviewed in 48, 49) . CSR takes places between repetitive, non-coding switch (S) region sequences that precede C H exons. Although the CSR mechanism by which two S regions are joined is not certain, dependence on DNA-PKcs and Ku suggests, but does not prove, a role for NHEJ and, by extension, DSBs (48, (50) (51) (52) . CSR requires activation-induced cytidine deaminase (AID), which is expressed only in activated B cells (53) (54) (55) . AIDknockout mice and AID-deficient humans are normal, except that B cells lack the ability to undergo CSR or SM (54, 55) . The AID-deficient CSR defect is direct, as cellular-activation events up to CSR are normal, and deficient mice or humans show B-cell hyperplasia in the form of enlarged GCs (54, 55) . Although the exact role of AID in initiating CSR is debated, recent studies have implicated AID in the initiation of this process as well as in the initiation of somatic mutation (reviewed in 56). AID is a DNA cytidine deaminase with specificity for single stranded DNA (58) . AID is thought to create abasic sites in DNA by a two-step process, where the enzymatic deamination of cytidine residues is followed by removal of the mismatched base pair by the base-excision machinery (57) (58) (59) (60) . By this route, AID may initiate class switching by introducing lesions in target S regions, which ultimately generate strand breaks, leading to the downstream events required to complete the process (57) (58) (59) (60) .
SM occurs in GC B cells and may occur at frequencies as high as 1/1000 nucleotides/cell/generation (reviewed in 61, 62) . SM occurs primarily within or near IgH or IgL variable region exons, requires transcription, and can occur in non-Ig gene sequences inserted in place of the variable region exon (63) . Recent studies implicated DSBs in SM (61, (64) (65) (66) and, while these findings remain controversial (67), AID is also required for the B-cell-specific SM reaction (54, 55) . In the context of the postulated SM mechanism, repair of AID-initiated abasic sites can be conservative, resulting in no mutation, or error prone, resulting in SM, and involves several DNA lesion repair pathways (57) (58) (59) (60) .
Whereas NHEJ has been well documented to resolve RAGinduced DSBs to complete the V(D)J-recombination reaction, less is known about the role of breaks or the relevance of DSBR during CSR or SM (56) . In part, assessment of the role of NHEJ factors in these processes has been hampered by the severe SCID phenotype conferred by NHEJ deficiencies, which results in an absent or dramatically reduced B-cell compartment. The B-cell compartment can be restored in Ku70-, Ku80-or DNAPKcs-deficient mice by the introduction of productively rearranged IgH and IgL knockin alleles (50, 51, 68, 69) . Resulting Ku-deficient B cells fail to produce IgH isotypes other than IgM, arguing that Ku is necessary for CSR. However, these findings are complicated by the observation that Ku-deficient B cells show a proliferative defect and display elevated levels of apoptosis, which may non-specifically interfere with CSR. Analogous studies of DNA-PKcs-deficient mice or SCID mice (which express low levels of a slightly truncated DNA-PKcs protein) revealed a variable compromise in CSR but normal cellular proliferation (68, 69) . While these findings support the notion that normal CSR requires NHEJ, other interpretations are possible. In this regard, Artemis-deficient B cells appear to undergo CSR normally (Rooney and Alt, unpublished data), suggesting the possibility of a non-NHEJ role for DNA-PKcs in the CSR reaction. Finally, the role of DSBs or NHEJ proteins in SM remains even more speculative.
Current models for SM predict that DSBs are indirectly related to SM and may arise as a secondary consequence of the true SM reaction (59, 60, 70, 71) . How these breaks are introduced is not known, and if breaks occur, how they are removed or resolved is also unclear. Thus, DSBR may not play a role in SM per se, but rather it may serve to repair DSBs that occur inadvertently during some phase of the mutation process. In this context, NHEJ or possibly HR would play a protective role, eliminating DSBs before potentially oncogenic translocations could occur. It will be of interest in the future to determine if DSBR deficiency affects the SM reaction or, more likely, predisposes cells undergoing SM to genome instability. These studies await the development of suitable experimental systems.
Non-programmed breaks
In addition to developmentally programmed DSBs, nonprogrammed DSBs can be caused by normal metabolic processes or environmental insults. Non-programmed DSBs can occur randomly throughout the genome or be predisposed to occur within certain regions. Random DNA breakage may occur as the result of intrinsic or extrinsic insults, including DNA replication fork collapse, attack of DNA by reactive natural metabolites or by exposure to environmental mutagens, or irradiation. The latter category represents a well-known source of potential genomic instability. Irradiation of mammalian cells is well documented to induce chromosomal translocations, activate cell cycle checkpoints, and to compromise cellular viability. Oncogenic DNA breaks caused by exposure to environmental mutagens probably contributes to many types of spontaneously occurring tumors (reviewed in 72, 73) .
Chromosomal fragile sites (CFSs) represent another type of non-programmed DNA break. Fragile sites are classically defined as chemically inducible, non-staining gaps in condensed chromosomes, and their distribution and breakage are not completely random. Common CFSs are present throughout the mammalian genome, and they tend to comprise repetitive, often AT-rich, DNA sequence elements (74) . Recent studies have provided insight into the mechanism of breakage at fragile sites, implicating stalled replication forks within the repetitive sequence (75) . Abnormal chromatin condensation within fragile sites may also play a role in DNA breakage. The observation that CFSs can stimulate chromosomal recombination, as evidenced by sister chromatid exchange, raised the possibility that fragile sites can contribute to the development of abnormal karyotypic features, such as translocations (76) . Additionally, several studies have indicated that the activation of CFSs can directly result in gene amplification by a variety of mechanisms (77) (78) (79) (80) . Thus, induction of CFS can result in non-programmed, but non-random, DNA breakage that can subsequently lead to genomic instability.
Telomere dysfunction
Conservative DNA end replication represents a unique challenge in eukaryotic cells, which have linear chromosomes. This problem is solved by the ribonucleoprotein complex telomerase, which acts as a specialized reverse transcriptase dedicated to replication of the repetitive telomere sequences that terminate linear chromosomes. Eukaryotic telomeres are comprised of repetitive DNA sequences of variable length and a variety of associated proteins that protect chromosome ends from degradation or end-to-end fusions (reviewed in 81, 82) . The NHEJ factors, Ku80 and DNA-PKcs, which normally participate in ligation of broken DNA ends, paradoxically appear to play a role in normal telomere maintenance and the suppression of end-to-end fusions (83) (84) (85) (86) .
Mice that are deficient in telomerase activity exhibit defects in proper chromosome end maintenance (reviewed in 87). These mice show telomere shortening that becomes increasingly manifested in successive generations. Critically short telomeres are subject to high rates of end-to-end fusion, and cells with critically short telomeres display substantial rates of chromosome instability. Telomere shortening also activates p53 and induces cell-cycle arrest and apoptosis (88) . In p53-mutant mice, telomerase deficiency leads to the formation of complex cytogenetic abnormalities as a result of end-to-end fusion, followed by breakage-fusion-bridge (BFB) cycles (89) . Similarly, inhibition of the telomere-binding factor, TRF2, results in telomere dysfunction and a high rate of end-to-end fusions that are dependent on the NHEJ factor Lig4 (90) . Together, the chromosomal instability of telomerase-deficient mice, p53 activation by shortened telomeres, and Lig4-catalyzed fusions of unprotected telomeres suggest that eroded telomeres mimic DSBs and are detected and repaired (or misrepaired) accordingly. How NHEJ factors can normally be required for telomere maintenance but also catalyze end-toend fusions when telomeres fail is an intriguing and open question.
Oncogene activation

Translocations and enhancers
Chromosomal instability can result in oncogene activation by translocation or gene amplification. Translocations can directly result in the activation of oncogenes by different mechanisms. First, elevated expression may result by proximity to strong transcriptional elements brought close to the target oncogene by translocation, such as in Burkitt's lymphoma (BL). BL cells contain a t(8;14) reciprocal translocation that juxtaposes c-myc and strong transcriptional regulatory elements within the IgH locus on chromosome 14 (discussed below). This translocation results in the potent transcriptional activation of c-myc, leading to overexpression and cellular transformation.
Translocations Translocations and fusion genes Translocations can result in the creation of a fusion gene that encodes a novel oncogenic protein. The Philadelphia (Ph) chromosome, associated with chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), represents this mode of oncogene activation through the generation of a BCR-ABL fusion protein with non-receptor tyrosine kinase hyperactivity that functions in the RAS-signaling pathway to drive cellular proliferation. The Ph chromosome is the product of a reciprocal translocation between the long arms chromosomes 9 and 22 (see 99, 100, for detailed reviews of CML biology). On chromosome 9, the breakpoints usually occur 5 0 of the second exon (e2) of the ABL gene, while the breakpoints on chromosome 22 predominantly fall within two regions, the major breakpoint cluster region (M-bcr) and the minor breakpoint cluster region (m-bcr). The resulting t(9;22)(q34;q11) adds a 3 0 portion of the ABL gene to the Mechanism of translocations Although the oncogenic outcome of translocations has been recognized for decades, the mechanisms that promote the formation of translocations are just beginning to be understood. DNA breakage has been implicated, because translocations must involve exchange of both DNA strands between participating chromosomes. Moreover, in the case of many lymphoid malignancies, chromosomal breakpoints can be pinpointed to the region targeted for cleavage by the RAG endonuclease on the Ig-containing chromosome and sometimes lead to telltale reciprocal RS joins via utilization of a cryptic RS sequence on the target chromosome, suggesting interchromosomal V(D)J recombination as a mechanism (reviewed in 103, 104) . Furthermore, products of interlocus V(D)J recombination between Ig light chain genes have been identified, further confirming that the V(D)J machinery itself can generate translocations (105) . However, a demonstration that DNA breaks directly lead to oncogenic translocations has been lacking in most cases. In addition, cellular pathways that normally prevent translocation formation have only recently been identified, and the pathways that promote translocations in the absence of normal DNA repair remain uncharacterized. Principle challenges in understanding the etiology of oncogenic translocations will be to define the molecular mechanisms that normally suppress translocation and to identify the processes that generate translocations when suppression fails.
Amplification
Gene amplification, originally discovered in the context of a mechanism by which cultured mammalian cells become resistant to an anti-cancer drug (methotrexate) (106) , is generally defined as an increase in the cellular copy number of a gene or genomic region relative to the rest of the genome. Amplification of proto-oncogenes is another common means of oncogene activation in numerous tumor types (reviewed in 107, 108) . In addition to contributing to cellular transformation, amplification of oncogenes often accompanies increasing karyotypic complexity, and it can be an indicator of poor prognosis or therapy resistance. However, the events leading to amplification within a tumor setting have remained obscure. Several studies using cell lines have implicated DNA breakage in the initiation of gene amplification in cells cultured under drug selection. CFS expression can trigger intrachromosomal amplification of genes conferring resistance to cytotoxic drugs (80) , as can site directed cleavage by the rare-cutting I-SceI endonuclease (77) . Although the contribution of DNA breakage to amplification of specific oncogenes in primary human tumors remains to be determined, one study has identified amplicon boundaries within a CFS in the case of a gastric carcinoma (78) . This finding suggests that DNA breaks can lead to oncogene amplification in vivo. Studies of gene amplification in cell lines have also provided evidence that p53 suppresses gene amplification (109) (110) (111) (112) . Thus, p53 deficiency may create a permissive environment within which unrepaired DSBs can persist and ultimately become misrepaired, leading to cytogenetic abnormalities including gene amplification (45) (46) (47) (113) (114) (115) . Indeed, several recently developed mouse models, described in detail below, have provided direct experimental evidence that specific DNA breaks can initiate oncogenic gene amplification in the context of p53 deficiency.
Deletions
In addition to translocations and gene amplifications, neoplastic cells may also harbor chromosomal deletions. While deletions can potentially result in oncogene activation by removal of negative regulatory elements or elimination of regulatory protein domains, it is more likely that a deletion will cause the loss of a tumor suppressor. This case is particularly true with large deletions that are cytogenetically detectable. Massive chromosomal deletion is frequently seen in myelodysplastic syndrome (MDS), a precursor to acute myeloid leukemia (AML), frequently affecting chromosomes 5, 7 and 20 (reviewed in 116, 117). One candidate tumor suppressor is the ETF1 translation factor on chromosome 5 (118), while candidate genes on chromosomes 7 and 20 remain to be elucidated. Another region commonly deleted in human tumors is 13q14. Deletions at this position have been observed in B-cell chronic lymphocytic leukemia (B-CLL) (119), nonHodgkin's lymphoma (NHL), and ALL (120) . Although several candidate tumor suppressor genes reside at this location, conclusive demonstration of their relevance remains elusive (121) .
Simple versus complex cytogenetics: mouse models and human tumors
Cytogenetic abnormalities in human tumors range from simple reciprocal translocations to extremely complex multipleparticipant translocations that are often non-clonal and highly variable. Such cytogenetic abnormalities are associated with tumors derived from a wide variety of tissue types, and they may affect overlapping oncogenes. Below, we outline the range of karyotypic abnormalities that can be associated with human cancer. (134, 136) . Such expression is probably required to support normal B-cell development and survival and could potentially be involved in tumor cell maintenance (134, 135) . FL B cells are monoclonal with respect to Ig receptor and translocation, implying that if the translocation occurred early in development, additional transforming events occur subsequently (reviewed in 129, 136).
Simple karyotypes: class switch recombination and translocations In contrast to eBL, sporadic BL (sBL) occurs at a low rate worldwide and is not typically found with Epstein-Barr virus (EBV) infection, except in those cases associated with acquired immune deficiency syndrome (reviewed in 127). Like eBL, most cases of sBL show the presence of the typical t(8;14) marker chromosome. Translocation breakpoint analysis of sBL cells revealed that chromosome 14 breakpoints often occur within the IgH switch regions that target CSR. Translocation breakpoints on chromosome 8 usually occur within the non-coding first exon or within the first intron of c-myc (reviewed in 128).
Like sBL, diffuse large cell lymphoma is associated with recurrent simple, reciprocal translocations, often affecting 3q27 (reviewed in 137, 138) . The Bcl-6 gene, which is deregulated by these translocations, is located at 3q27 and can be activated by recombination with Ig genes or non-Ig genes located at 8q24, 11q13, or 5q31. Breakpoints in translocations that activate Bcl-6 frequently occur within IgH switch regions, similar to sBL, and result in the replacement of native Bcl-6 regulatory elements with IgH regulatory elements. This finding suggests that these translocations occur as a result of mistakes in CSR resolution. Bcl-6 translocations that involve IgL genes occur less frequently, and they may arise as a result of receptor editing in GC B cells or potentially could occur early in B-cell development and persist until further molecular events lead to mature B-cell transformation (9, 137, 139) . Little is known about the molecular mechanisms for Bcl-6 translocations that involve non-Ig loci. However, the common theme of these translocations is the retention of intact Bcl-6-coding sequences and hyperactivation by enhancer/ promoter recruitment (reviewed in 137).
Mouse plasmacytomas (MPCs), like BL, represent a lymphoid malignancy associated with a characteristic balanced translocation involving Ig genes and c-myc (reviewed in 140, 141) . MPC is a neoplasm of the fully differentiated lymphoid plasma cells. Mice in a BALB/c genetic background are highly susceptible to plasmacytomagenesis, following administration of the mineral oil pristane (142) . Greater than 90% of such pristane-induced MPCs contain a characteristic reciprocal translocation between chromosome 12, where the murine IgH locus resides, and chromosome 15, where murine c-myc resides (143, 144) . Analysis of translocation breakpoints in pristane-induced MPCs has revealed that the t(12;15) translocation is reminiscent in several ways of the t(8;14) seen in sBL. Translocation breakpoints on chromosome 12 typically fall within an S region of the IgH locus, while chromosome 15 breakpoints usually reside within the first exon or the first intron of c-myc. Translocations involving S regions do not result in juxtaposition of the intronic IgH enhancer to the c-myc gene, consistent with a role for the 3 0 IgHRR.
Simple karyotypes: immunoglobulin L translocations Although roughly 75% of BL cases contain a t(8;14) translocation, a minority of both eBL and sBL contain variant translocations (reviewed in 127). Abnormalities in variant BL cases involve chromosome 8 and either the Ig light chain k locus on chromosome 2 or the Ig light chain l locus on chromosome 22 (128) . Unlike the common breakpoints that occur within or 5 0 of c-myc, variant translocation breakpoints on chromosome 8 occur far 3 0 of c-myc and involve the distal long arm portion of the chromosome containing the IgL locus (2 or 22) . This placement puts the IgL gene in the same transcriptional orientation as c-myc and generates a translocation product that is derived from the centromere of chromosome 8 and the telomere of chromosome 2 or 22. A minority of translocations observed in MPCs, as with BL, represent the variant class, and they involve the Ig k or l light chain loci (144) .
Complex karyotypes While lymphoid tumors frequently contain recurring translocations, karyotypic changes in many other human tumors have proven to be much more complex. The majority of human tumors are in fact solid tumors, which together comprise over 90% of human malignancies. Studies of karyotypes of solid tumors over several decades have left no doubt that genomic instability is a crucial feature. However, the changes are much more complex than in most lymphoid tumors, including variability between histologically identical tumors as well as cell-to-cell variability within a tumor. Changes include aneuploidy, which ranges from subdiploid to more than tetraploid, single chromosome losses and gains, and genomic amplifications and deletions. Translocations are often observed, but they are highly variable and often include more than two chromosomes, making analysis by traditional karyotyping challenging (108, 145) . This level of complexity can frustrate efforts to pinpoint relevant abnormalities among the background of complexity and often hampers the identification of precise regions participating in chromosomal translocations.
Jumping translocations (JTs) and segmental JTs (sJTs) represent examples of such complex events. JTs are unbalanced translocations that involve an entire chromosome arm becoming translocated to any of a variety of partner chromosomes. Related to JTs, sJTs result in a segment of a chromosome arm, becoming attached to a variety of recipient chromosomes. JTs and sJTs have been observed in cells derived from carcinomas of the skin, pancreas, bladder, breast, prostate, and cervix (145, 146) . JTs can sometimes be found in leukemias and other hematopoietic malignancies, where they often accompany oncogene amplification and contribute to evolving karyotypic complexity (147, 148) .
Gene amplification is also commonly seen in solid tumors and can occur with or without the appearance chromosomal translocations. The dramatic amplification of N-myc observed in neuroblastomas exemplifies this mode of oncogene activation (149) (150) (151) . In neuroblastoma cell lines, N-myc can be amplified as much as 700-fold and can appear on homogeneously staining regions (HSRs), double minutes (DMs) or in novel chromosomal locations (150) . N-myc amplification is also observed in 20-40% of primary neuroblastomas. The role of oncogene amplification in tumorigenesis generally appears to be linked to tumor progression; in this regard, amplification of oncogenes, such as N-myc, often accompanies increasing karyotypic complexity and strongly correlates with disease progression, being predictive of poor clinical outcome (152) . Gene amplification also features prominently in other tumors, including cancers of the breast, lung, bladder, and several types of sarcomas (reviewed in 108). In these tumors, amplification can affect numerous different loci and, like N-myc, often correlates with disease progression and poor prognosis (reviewed in 108, 109).
Oncogene amplification is less frequently seen in hematologic malignancies, being principally associated with MDS and AML. Gene amplification in myeloid leukemia, like solid tumors, is associated with the acquisition of complex karyotypic features. A subset of AML patients contain ring chromosomes or DMs with amplification of c-myc, MLL, or less frequently AML1 (reviewed in 100). Presence of DMs and ring chromosomes is typically affiliated with the appearance of complex karyotypes, and it is generally an indicator of adverse prognosis, due to increased aggressiveness (153) (154) (155) (156) (157) . A comprehensive census of published comparative genomic hybridization studies data compiled from over 11 000 tumors since 1992 indicated that recurrent deletions and amplifications afflict a multitude of chromosomal loci and occur across a broad spectrum of cell types (158) . Therefore, it is of significant interest to understand the molecular mechanisms that lead to gene amplification.
Recently, the mouse model of telomere erosion described above has provided compelling evidence that the substantial genome instability resulting from telomere failure can directly contribute to tumorigenesis (88, 89) . Telomere fusions between non-homologous chromosomes can produce translocations as a precursor to oncogene amplification and may thus contribute to the genomic instability observed in some human solid tumors (reviewed in 87). Since eroded telomeres appear to mimic true DSBs, oncogenic translocations and amplification, in the context of telomere erosion, may occur by a mechanism related to that associated with bona fide DSBs (see below).
Multiple myeloma: evolution from simple to complex
Many of the features of genome instability related to DSBs, as outlined above, are associated with the development and progression of multiple myeloma. Multiple myeloma is a terminally differentiated B-cell (plasma cell) neoplasm arising within the bone marrow and is characterized by monoclonal Ig secretion and osteolytic bone lesions (reviewed in 159). In its premalignant phase, multiple myeloma presents as monoclonal gammopathy of unknown significance (MGUS), which secretes monoclonal Ig and later progresses to overt multiple myeloma. Unlike most hematologic malignancies, multiple myeloma cells frequently contain complex karyotypes, more reminiscent of solid tumors (reviewed in 160). These karyotypes include both balanced and unbalanced translocations as well as aneuploidy and gene amplification and deletion. Despite this karyotypic complexity, some recurrent chromosomal abnormalities are observed. Early in the pathogenesis of the disease, initiating primary translocations are usually simple reciprocal events that juxtapose IgH, or rarely IgL, regulatory elements and target oncogenes. For example, IgH heavy chain translocations are present in 50% of MGUS cases and in up to 80% of myeloma cases (reviewed in 160).
Primary translocations in multiple myeloma, like other lymphoid neoplasms, derive from errors in resolution of programmed DNA lesions, in this case apparently during CSR. As noted above, CSR may be initiated by DSBs, staggered single-strand nicks or other DNA-strand lesions, which, like RAG-induced breaks, may be subject to misrepair. The role of DSBs in promoting primary translocations in multiple myeloma has, at present, only been inferred, and remains to be formally demonstrated. Translocation breakpoints in multiple myeloma are commonly observed within IgH switch region sequences (reviewed in 161). As a result, the downstream region of the IgH locus, including the 3 0 RR, becomes fused to any of a variety of partner chromosomes and results in the activation of one of several different oncogenes, including cyclins D1 or D3, FGFR3, or c-myc (reviewed in 160, 161). As these deletions generally lack the intronic Em enhancer elements, the 3 0 RR may be the key element in activation, but this role also remains to be proven. Occasionally, translocations result in IgH breakpoints located downstream of Ig V gene promoters in the region targeted for SM, suggesting that oncogenic translocations may also arise in activated B cells as a result of errors in SM.
As the disease progresses and the karyotype becomes increasingly complex, additional oncogenes are activated leading to the acquisition of a highly proliferative, highly aggressive state (reviewed in 159, 160). Secondary translocations do not involve known programmed DSBs and can involve multiple chromosomes, JTs, sJTs, and gene amplification. Thus, progression of multiple myeloma is associated with the acquisition of complex cytogenetic changes that are reminiscent of many solid tumors. Although the stages of multiple myeloma progression have been noted phenomenologically (161), the underlying molecular basis for the generation of either simple primary or complex secondary translocations remains unknown. However, one intriguing hint comes from the observation that certain Lig4 polymorphisms can modulate the predisposition to multiple myeloma (162) . The detailed elucidation of processes influencing multiple myeloma will require more refined techniques for dissecting complex karyotypes and will benefit from the development of increasingly accurate mouse models of complex tumor evolution.
A mouse model of complex oncogenic karyotypic changes
Non-homologous end joining/p53-deficient mice: pro-B-cell tumors Mice that are deficient for XRCC4, Lig4, or Ku or are homozygous for the murine SCID mutation (which results in a truncated DNA-PKcs) in combination with p53 deficiency (referred to as X/P, L/P, K/P, or S/P, respectively; collectively as N/P) routinely succumb to pro-B-cell lymphomas at a young age (45-47, 113, 163-165) . These lymphomas are characterized by the nearly invariant presence of a der(12)t(12;15) marker chromosome, termed C12;15 to denote a non-reciprocal translocation containing the centromere of chromosome 12 (46, 47, 164) . The C12;15 product is reminiscent of the t(8;14) classically associated with BL, except that reciprocal derivative 15 translocation products are not seen in N/P lymphomas. Instead, these tumors contain multiple, often complex, chromosomal abnormalities (113) (114) (115) . Southern blot analyses indicated that these tumors harbored clonal rearrangements within the J H cluster in IgH, consistent with pro-B origin. In addition, these studies demonstrated that IgH (chromosome 12) and the c-myc oncogene (chromosome 15) are commonly amplified, further distinguishing these from BL (46, 47) . Cytogenetic analyses of N/P lymphomas using single chromosome paints in conjunction with specific fluorescence in situ hybridization probes further revealed that co-amplified c-myc and IgH sequences were not located on C12;15 as expected. Rather, the c-myc/ IgH amplicon was located on a der(15) complex translocation product that usually contained the centromere of chromosome 15, co-amplified chromosome 12 and 15 material, and a distal segment of a variable third chromosome (113) (114) (115) . To indicate the presence of an amplicon on these complex translocations, we have termed these structures complicons (114) (Fig. 1) .
Sequencing of translocation junctions in N/P tumors revealed breakpoints that reproducibly occurred within the J H cluster on chromosome 12, but they were widely dispersed on chromosome 15 in a region from 70 to 700 kb downstream of (and therefore centromere-distal to) c-myc (114, 115) . This location contrasts sharply with the arrangement of IgH and c-myc in most other hematologic malignancies, where IgH sequences are translocated upstream of c-myc and in relative proximity (reviewed in 127). Examination of translocation junction sequences revealed that fusions occur at regions of microhomology ranging from 1 to 6 bp (114, 115), although one K/P lymphoma apparently harbored a blunt ligation (115) . Which DNA repair and processing machinery catalyze microhomology-dependent recombination and fusion of sister chromatids is currently a mystery.
Previous studies of NHEJ-deficient cells have also demonstrated a micro-homology mediated recombination mechanism that catalyzes low-level aberrant V(D)J recombination (16, 166, 167) . It is unknown if this pathway is constitutively active but is normally masked by a more efficient NHEJ pathway or if microhomologous joining only takes over in the absence of classical NHEJ. Microhomology-mediated end joining has been noted as a DSBR pathway that is distinct from the better characterized HR and NHEJ pathways (168) and may rely, in part, on BRCA1 (169). The contribution of this pathway to the normal repair of DSBs and the maintenance of genome stability are not known. However, in the absence of normal NHEJ and p53, this microhomology joining is oncogenic, as it catalyzes interchromosomal recombination, resulting in translocations. Thus, it will be of significant interest to determine if this oncogenic DNA joining pathway is also active in human tumors.
The highly recurrent presence of clonal J H rearrangements in N/P lymphomas strongly suggested that RAG endonucleasecatalyzed breakage, known to occur within this region in normal pro-B cells, led to formation of the C12;15 translocations. The dependence of these tumors on RAG was formally demonstrated by introducing RAG2 deficiency into N/P mice. The resulting triply deficient (N/P/R) mice did not develop pro-B-cell lymphomas (114, 115, 164) . Of note, another recent study has suggested that, in some cases, the genomic instability conferred by simultaneous NHEJ and p53 deficiencies is sufficient for pro-B-cell tumorigenesis, even in the absence of RAG cleavage (113) . In this study, S/P mice that were also deficient of RAG still developed tumors that cellsurface marker analyses indicated were of pro-B origin. However, these tumors were distinct from those that arose in the RAG-sufficient S/P background in that they did not contain the signature t(12;15) translocation and tended to disseminate into the leptomeningeal space (113) . Others have reported that S/P/R (and K/P/R) mice develop only thymic lymphomas that lack specific translocations and that occur with approximately the same age of onset as those that arise in mice harboring p53 deficiency alone (115, 164) . The differences between these studies remain to be fully resolved, but they could be due to strain-specific modifier genes. However, the fact that pro-B-cell lymphomas without the t(12;15) translocation were not observed in any RAGproficient background indicates that the RAG-induced tumors occurred much earlier, even in mixed genetic backgrounds (reviewed in 87). Taken together, these studies indicate that RAG-dependent cleavage of the IgH locus greatly potentiates the formation of oncogenic translocations, but that in the absence of RAG cleavage, the underlying genomic instability in N/P mice can, at least in some backgrounds, still predispose to tumorigenesis faster than either NHEJ or p53 deficiency alone (see below).
Non-homologous end joining-deficient mice: non-B-lineage neoplasia NHEJ deficiency leads to spontaneous genomic instability in many cell types, even when cell cycle checkpoints are intact. This observation seems to predict that tumors should be prevalent in NHEJ-deficient animals. Indeed, SCID mice as well as mice containing knockout alleles of Ku70 or DNA-PKcs are susceptible to T-lineage lymphomagenesis (170) (171) (172) (173) . However, these mice do not typically succumb to tumors derived from other tissues or other hematopoietic lineages. The lack of widespread tumor predisposition may attest to a need for cell cycle control defects or other mutational changes for the formation of most tumors.
Recently, histologically detectable medulloblastomas, primitive neuroectodermal tumors arising from the granule cell precursors of the external germinal layer of the cerebellum, have been reported to develop in L/P mice (174) . Additionally, one X/P/R mouse analyzed showed histologic evidence of two microscopic medulloblastomas (114) . These findings support the notion that, in addition to NHEJ defects, cell cycle checkpoint deficiencies precede tumor formation. These findings also suggest that the cerebellum is acutely sensitive to chronic unrepaired DSBs, but how the end joining deficiency contributes to transformation of cerebellar granule cell precursors is not known. These mice have not been reported to develop other nervous system tumors. In the case of S/P/R, pre-T-cell leukemia developed with low penetrance, and a small fraction developed sarcomas, but these were similar to those arising in p53 deficiency alone (113, 164) . Surprisingly, other than the medulloblastomas noted above, N/P/R mice have not been reported to develop overt, non-lymphoid tumors that are distinguishable from those that arise as a consequence of p53 alone (113-115, 164, 175, 176) . This finding is curious, because the NHEJ deficiency in these mice should result in the presence of chronic unrepaired DSBs with oncogenic potential. As detailed necropsies or histological analyses of most N/P/R mice were not reported, it is possible that indolent tumors were undetected. A full understanding of the spectrum of tumor susceptibility in N/P/R mice awaits mice with conditionally inactivatable alleles of NHEJ genes.
Molecular model for complicon formation
In N/P pro-B-cell lymphomas, a paradox exists when one considers how a single broken chromosome 12 can invariably result in two translocations -the C12;15 and the complicon This paradox cannot be explained by invoking the rearrangement of independent broken chromosome 12s, since one apparently normal 12 is always found in each tumor. It can most likely be explained by a mechanism in which the replication of a broken chromosome 12 occurs. RAG generates DSBs in G0 or G1 of the cell cycle (177) prior to DNA replication, but p53 normally induces apoptosis in response to unrepaired DSBs (178) . In the absence of p53, pro-B cells with RAGinitiated DSBs will survive, allowing the broken 12 to be replicated in S phase and subsequently undergo recombination with chromosome 15 (Fig. 2) . In support of this model, one L/P lymphoma yielded an inverted J H fusion (114) , providing evidence, given that the cells contained a normal chromosome 12, that the broken chromosome 12 can indeed be replicated prior to recombination in these tumors.
As noted above, cloned translocation junctions revealed that breakpoints on chromosome 15 occurred predominantly 3 0 of c-myc, and the presence of 3 0 junctions appeared to correlate with the amplification of c-myc (114, 115) . Further scrutiny of the translocation junction sequences revealed that the participant chromosomes 12 and 15 were oriented to yield a dicentric translocation product. Dicentric chromosomes are a well-known source of chromosomal instability. BFB cycles following the formation of dicentric chromosomes (179) are one common mechanism for intrachromosomal gene amplification in cells cultured under selection with cytotoxic drugs (180) . In this context, we envisage dicentric translocation products resulting from recombination between chromosome 12 and chromosome 15, initiating BFB cycles that produce the observed co-amplification of c-myc and IgH (Fig. 2) . In further support of this model, several key structures that are predicted intermediates were observed. These include ring chromosomes and dicentric chromosomes with co-amplified c-myc and IgH at their center (114, 115) . It is curious that in N/P lymphomas c-myc is so frequently amplified but is rarely activated by IgH enhancer recruitment alone, as is the case in many other lymphoid malignancies (reviewed in 127, 159) . It is also intriguing that the chromosome 15 breakpoints occur almost exclusively distal to c-myc and are distributed across a roughly 700-kb region. Why do N/P lymphomas display such strong bias toward c-myc activation by complicon formation versus IgH enhancer recruitment? Although alternative models cannot be absolutely excluded, we favor the explanation that any translocation breakpoint distal to c-myc that results in the formation of a dicentric product is sufficient to initiate BFB cycles in a p53-deficient background. Therefore, the target region for initiating translocations in N/P lymphomas is quite large and non-specific, and breakpoints can be distant from the target oncogene (c-myc). Subsequent amplification of c-myc in N/P lymphomas is rapid and inevitable via BFB cycles, and therefore c-myc becomes quickly activated. This contrasts with the activation by enhancer recruitment, which may require more specific breakpoints to create discrete translocations that bring ectopic enhancers into appropriate proximity to exert transcriptional upregulation. Thus, the target genomic region for activation by enhancer recruitment is smaller, and the translocations that activate c-myc by this mode may be more rare.
Complicons versus simplicity We believe that complicons are not typically seen in many naturally occurring lymphoid malignancies in humans and mice, because two preconditions to complicon formation are not met. First, unrepaired DNA breaks must be present. This condition is satisfied in N/P mice, because the NHEJ deficiency results in failure to repair RAG-induced DSBs. In the case of most human lymphoid tumors, DSBs probably do not persist. Breaks occur in the context of functional NHEJ, and thus, translocations are relatively rare. Second, complicon formation requires cell cycle checkpoint deficiency. N/P progenitor B cells are deficient of p53 even prior to cellular transformation, so RAG-induced breaks can be rapidly converted into translocations. When these form dicentric chromosomes, DSBs that result from subsequent BFB cycles are also allowed to persist. If, by contrast, dicentric chromosomes arise in the context of normal checkpoint activity, cells would undergo growth arrest or apoptosis when the dicentric chromosome got broken during the ensuing BFB cycle. Thus, in premalignant cells with normal checkpoint activity, the formation of a translocation that preserves normal chromosomal structure (one centromere and two telomeres) would be favored over the formation of a dicentric chromosome, a critical complicon intermediate (114) . Because the preconditions to complicon formation are satisfied in N/P mice even prior to tumor formation, N/P lymphomas may represent a useful model to analyze molecular events following DNA breakage that lead to complex cytogenetics associated with human solid tumors.
Implications for human tumors
The role of DNA breaks The complex karyotypes seen in murine pro-B-cell lymphomas described above are atypical of hematologic malignancies and more resemble the situation in advanced stage human solid tumors, where increasing complexity often accompanies increasing aggressiveness and poor prognosis (181) . The initiating lesion in the case of N/P pro-B lymphoma is RAG cleavage of the IgH locus in the J H region, but there is no known corresponding DNA-breakage program in most tissues giving rise to solid tumors. This finding raises the question of whether DNA breakage is relevant to the acquisition of complex karyotypic features in human solid tumors. At present, this question remains outstanding, and it awaits the experimental means to monitor the molecular events involved in tumor progression within an in vivo setting.
Several lines of evidence suggest that DSBs are indeed relevant to tumor progression, as indicated by increasing cytogenetic plasticity. First, specific DSBs are now well documented to induce chromosomal translocations in cell lines and experimental model systems (114, 115, 182, 183) . Second, gene amplification often accompanies tumor development or progression (reviewed in 109), and several recent studies have provided compelling evidence that DNA breakage can stimulate gene amplification in cells under selective growth conditions (77, 184, 185) . Third, p53 is often found mutated in human cancers, and in cases where p53 itself is found intact, its downstream effectors are often mutated (reviewed in 186). Compromise of the p53 pathway provides a permissive environment for the retention of DSBs and the subsequent generation of chromosomal abnormalities (111, 112) . Fourth, compounds that can induce DSBs are well known to act as environmental carcinogens, thus providing a link between tumorigenesis and extrinsically induced DNA breakage (72, 186) . Fifth, telomerase deficiency in mice indicates that DNA lesions at the ends of chromosomes can be treated as DSBs and lead to the formation of chromosomal translocations and amplifications (89, 90) . Finally, the translocations discussed in this review arising in N/P pro-B-cell lymphomas clearly demonstrate a direct link between in vivo DSBs, the acquisition of complex karyotypes, and tumorigenesis in vivo.
Human double-strand break repair deficiencies Several human diseases are characterized by sensitivity to ionizing radiation, genomic instability, and cancer predisposition, suggestive of defects in the repair of DNA damage. These include, among others, AT, Nijmegen breakage syndrome, Fanconi anemia and Bloom's syndrome (reviewed in [188] [189] [190] . Although each of these diseases is thought to result, in part, from defects in DSBR, the affected proteins have pleiotropic effects on DNA repair or function as upstream regulatory factors coordinating DSBR by multiple pathways (1, (188) (189) (190) . While studies of NHEJ-deficient mice have indicated a key role for this pathway in the suppression of tumors, human DSBR deficiencies need not exclusively affect NHEJ (e.g. they could affect HR). Moreover, while a G1 checkpoint activity for p53 is critically involved in tumor suppression in NHEJ-deficient mice, human checkpoint deficiencies are not necessarily exclusive to G1 (e.g. ATM or ATR in G2). At present, the involvement of defects in the major DSBR pathways, NHEJ and HR, in sporadic human tumors is largely undetermined. This area is one of active ongoing investigation, but the findings from the N/P lymphoma model systems argue that DSBR deficiencies could underlie instances of chromosomal instability in human tumors, particularly those of advanced stage with highly abnormal karyotypes.
Heterozygosity for Lig4 accelerates soft tissue sarcoma formation in Ink4a/Arf-null mice, and these tumors are associated with karyotypic abnormalities that resemble those seen in human tumors (191) . This finding suggests that decreased dosage of an NHEJ factor, as opposed to complete inactivation, can support organismal viability and, importantly, predispose to non-lymphoid tumor formation in the right context. NHEJ mutations have also recently been identified in human patients with immunodeficiency. These include Lig4 mutations that confer developmental defects and cellular IR hypersensitivity (Lig4 syndrome) (192) . These patients possess apparently normal cell cycle checkpoint activities but are compromised in NHEJ. Lig4 syndrome patients have not yet presented with tumor predisposition, but definitive information in this regard will require long-term follow-up and additional patients. In addition, mutations in the NHEJ factor Artemis are responsible for the related human disorders, SCIDA and RS-SCID, which are characterized by the absence of mature B and T lymphocytes and a hypersensitivity to IR (28) . A crucial role for Artemis in maintaining genomic stability in murine cells has been demonstrated (31) , and hypomorphic alleles of Artemis in humans have been implicated in the development of lymphomas which harbor clonal karyotypic aberrations (193) . Finally, recent reports have implicated variant alleles of the HR factors, XRCC2 or XRCC3, with increased risk for certain tumors, although this remains controversial (194) (195) (196) (197) (198) .
The identification of variant or mutant alleles of pathwayspecific DNA repair genes raises the possibility that such insufficiency in combination with inherited or spontaneous mutations in p53 or other relevant checkpoint pathways could lead to the formation of oncogenic chromosomal abnormalities. It will therefore be of great interest to determine which, if any, DSBR pathways are compromised in sporadic human tumors, especially those that display dramatic cytogenetic irregularities. It will further be of interest to determine if DSBR defects can form the basis of yet uncharacterized familial tumor predisposition syndromes.
